Cholangiocarcinoma is a life-threatening disease with a poor prognosis. Although genome analysis unraveled some genetic mutation profiles in cholangiocarcinoma, it remains unknown whether such genetic abnormalities relate to the effects of anticancer drugs. Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) are exclusively found in almost 20% of intrahepatic cholangiocarcinoma (ICC). Recently, the anticancer effects of BET inhibitors including JQ1 have been shown in various tumors. In the present study, we report that the antigrowth effect of JQ1 differs among ICC cells and IDH1 mutation sensitizes ICC cells to JQ1. RBE cells harboring IDH1 mutation was more sensitive to JQ1 than HuCCT1 or HuH28 cells with wildtype IDH1. JQ1 induced apoptosis only in RBE cells through the upregulation of proapoptotic genes BAX and BIM. We found that the antigrowth effect was not attributed to downregulation of the MYC gene as a well-known target of JQ1 in various cancer cells. Notably, the forced expression of mutant IDH1 successfully sensitized HuCCT1 cells to JQ1. In addition, AGI-5198, a selective inhibitor of mutant IDH1 partially reversed the decrease in viability after JQ1 treatment and also suppressed the JQ1-induced apoptosis in RBE cells. These data suggest that IDH1 mutation contributed to the growth inhibitory effect of JQ1 in RBE cells. Furthermore, given that the effect of mutant IDH1 was not recapitulated in glioblastoma cells, the enhancement of JQ1 sensitivity by IDH1 mutation seems to be specific for ICC cells. Our findings propose a new stratified therapeutic strategy based on IDH1 mutation in ICC.
| INTRODUCTION
Biliary tract cancer (BTC) is classified by anatomical location into intrahepatic (ICC), extrahepatic (ECC) cholangiocarcinoma, and gallbladder cancer. 1 Although congenital biliary malformations, hepatobiliary flukes, and chronic inflammation, including primary sclerosing cholangitis or viral hepatitis, are known as risk factors, a large proportion of BTC often arise without obvious causes. 2, 3 Although the incidence of BTC has gradually increased, its prognosis remains unfavorable and the 5-year survival rate is less than 5%-10%. 4, 5 This is because few effective antitumor regimens exist for advanced BTC. 2, 4, 6 Recent sequence studies have identified genomic abnormalities in BTC, with clear distinctions among the different anatomical BTC subtypes. 1, [7] [8] [9] Somatic gene alterations in kinase-RAS modules (EGFR, ERBB3, and PTEN) are specifically seen in gallbladder cancers. 1 This is in agreement with our previous reports that the combinatorial inhibition of MAPK and PI3K mammalian target of rapamycin pathways exerted antigrowth effects in gallbladder cancer cells. 10 
TP53
and SMAD4 genes are more frequently mutated in a set of liver fluke-associated BTC. In contrast, somatic mutations in some chromatin remodeling genes, including BAP1, IDH1/2, ARID1A, and PBRM1 are found in non-infection-associated BTC, [7] [8] [9] which suggests the possibility that the dysregulation of chromatin remodeling might be involved in the development of BTC.
Isocitrate dehydrogenase (IDH) is the enzyme responsible for the conversion of isocitrate to α-ketoglutarate (α-KG) in the cytosol (IDH1) and mitochondria (IDH2). 11 When the mutation occurs in the catalytic site of the enzyme, a specific metabolite R(-)-2-hydroxyglutarate (2-HG) is produced from α-KG. 12 2-HG inhibits the activity of α-KG-dependent histone and DNA demethylases, which leads to epigenetic alterations. 13, 14 It is reported that 2-HG-mediated epigenetic dysregulation may lead to impaired differentiation of various progenitor cells and, ultimately, to carcinogenesis. [15] [16] [17] [18] Consistently, IDH1/2 mutations have been identified in several types of malignancies, including glioma, acute myeloid leukemia, and cartilage tumors. [19] [20] [21] In BTC, IDH1/2 mutations occur in 8%-25% of ICC, but not in ECC Bromodomain and extraterminal domain (BET) family proteins (BRD2, BRD3, BRD4, and BRDT) recognize acetylated lysine residues on histone tails and facilitate transcriptional activation through the recruitment of transcriptional regulatory complexes. 24 Recent reports proposed that JQ1, a selective inhibitor of BET proteins, exerts antigrowth effects in many types of cancer, inducing cell cycle arrest in cancer cells followed by the downregulation of the MYC oncogene. [25] [26] [27] [28] [29] [30] However, the efficacy of JQ1 for BTC remains unknown. 30 In the present study, we investigated the therapeutic efficacy of JQ1 for ICC cells and identified the possible involvement of mutant IDH1 in the sensitivity to JQ1.
| MATERIALS AND METHODS

| Cell lines
HuCCT1 and HuH28 cells were obtained from JCRB cell bank (Osaka, Japan). RBE cells were obtained from Riken Cell Bank (Tsukuba, Japan). U-87MG and IDH1 mutant-U87 isogenic cells were obtained from ATCC (Manassas, VA, USA). HuCCT1, HuH28 and RBE cells were cultured in RPMI-1640 (Sigma-Aldrich, St Louis, MO, USA) media supplemented with 10% FBS (Invitrogen, Carlsbad, CA, USA), 100 units/mL penicillin, and 100 μg/mL streptomycin. U-87MG
and IDH1 mutant-U87 isogeneic cells were cultured in E-MEM (Wako Pure Chemical Corp., Osaka, Japan) media supplemented with 10% FBS (Invitrogen), 100 units/mL penicillin, and 100 μg/mL streptomycin. All cells were maintained at 37°C and 5% CO 2 .
| Reagents
(+)-JQ1 (JQ1) was purchased from MedChem Express (Princeton, NJ, USA). AGI-5198 was purchased from Cayman Chemical (Ann Arbor, MI, USA).
| Cell viability and proliferation assay
Cell proliferation was assessed using CCK-8 (Dojindo, Kumamoto, Japan Values were normalized to the expression of ACTB mRNA. Primers used in this study are shown in Table S1 .
| Caspase-3/7 activity
Cells were seeded at 2 × 10 3 cells per well in 96-well plates. On the following day, the cells were treated with JQ1, AGI-5198, or a combination of both at the indicated concentration. After 48 hours, caspase-3/7 activity was assessed by using a Caspase-Glo 3/7 Assay (G8090; Promega, Madison, WI, USA) in accordance with the manufacturer's protocol.
| DNA sequencing
Genomic DNA was extracted from incubated cells using a QIAamp DNA Mini Kit (Qiagen) in accordance with the manufacturer's protocol. Extracted DNA was amplified by PCR. The primer sequences used to amplify IDH1 exon 4 (R132) were 5′-TCAGAGAAGCCAT TATCTGCAAAAATAT-3′ (forward) and 5′-GGCCATGAAAAAAAAAA CATGC-3′ (reverse). The PCR cycling conditions were 95°C for 10 minutes, 40 cycles of (95°C for 30 seconds, 50°C for 30 seconds, 72°C for 30 seconds), and 72°C for 7 minutes. Successfully amplified DNA was analyzed by using the direct sequence method.
| Lentiviral-mediated gene knockdown
For knockdown experiments, the lentiviral plasmids expressing specific shRNAs were obtained from Open Biosystems (Huntsville, AL, USA). The clones used were as follows: sh-MYC-1 (TRCN0000174055) and sh-MYC-2 (TRCN0000039640). Viral particles were produced in 293T cells as previously described. 31 Lentiviruses expressing shRNAs were infected to RBE cells in the media with polybrene (8 μg/mL). After 24 hours, transfected cells were selected with puromycin (4 μg/mL).
| Forced expression of mutant IDH1
Human wild-type IDH1 expression vector (pFN21AE0433) was purchased from Kazusa DNA Research Institutes (Chiba, Japan). The IDH1 R132S mutant was generated from wild-type IDH1ORF in this plasmid using a QuikChange Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA) and primers 5′-GATCCCCA-TAAGCATGACTACCTATGATGATAGGTTC-3′ for sense and 5′-GA-ACCTATCATCATAGGTAGTCATGCTTATGGGGATC-3′ for antisense.
The wild-type and mutant IDH1 were ligated into the multiple cloning sites of pLVSIN-CMV Vector (TAKARA Bio Inc., Kusatsu, Japan).
Viral particles were produced in 293T cells as previously described.
31
HuCCT1 cells were infected with lentiviruses for 12-16 hours and selected with hygromycin (800 μg/mL).
| Chromatin immunoprecipitation
Chromatin immunoprecipitation was carried out as described previously. 29 Briefly, HuCCT1 and RBE cells (2 × Table S2 .
| Statistical analysis
Data are presented as means ± standard error of the mean (SEM).
Statistical significance was evaluated by two-tailed Student's t test.
Differences were considered statistically significant at P < 0.05.
| Results
| Sensitivity to JQ1 differs among ICC cell lines
Three ICC cell lines; RBE, HuCCT1, and HuH28, were treated with 
| JQ1 suppresses G1/S transition in ICC cells regardless of the subsequent antigrowth effect
It is reported that the antitumor effects of JQ1 occur mainly in a cytostatic way in various cancer cells. 26, 27 Cell cycle analysis showed that JQ1 suppressed G1/S transition not only in RBE cells, but also in HuCCT1 cells (Figure 2A) . Consistent with the cell cycle analysis, expression of the CDK inhibitor gene p21 was upregulated in both cell lines ( Figure 2B ). Western blotting also confirmed the induction of p21 protein in both the JQ1-treated cell lines ( Figure 2C ). However,
given the subsequent growth in HuCCT1 cells ( Figure 1B) , it was clear that the difference of antiproliferative effects between the two cell lines could not be explained by the alteration of cell cycle kinetics.
| JQ1 induces apoptosis in RBE but not in
HuCCT1 cells
Despite the similar suppression of G1/S transition, only RBE cells, but not HuCCT1 cells, were detached from the culture dish after 48 hours (1 μmol/L) for 24 h and stained with propidium iodide (PI) for cell cycle analysis by flow cytometry. Data are presented as mean ± SEM (n = 3, **P < 0.01, ***P < 0.001, Student's t test). B, Gene expression of p21, relative to ACTB, was determined by qRT-PCR. Data are presented as the mean ± SEM (n = 4, **P < 0.01, ***P < 0.001, Student's t test). C, Protein expression level of p21 was assessed by western blotting. Asterisk indicates a non-specific band FUJIWARA ET AL.
| 3605 of JQ1 treatment ( Figure 3A) . From these phenomena, we estimated the induction of apoptotic cell death in JQ1-treated RBE cells and analyzed caspase-3/7 activity in both cell lines. Caspase-3/7 was activated after JQ1 treatment in RBE cells, but not in HuCCT1 cells ( Figure 3B ).
Western blotting confirmed that the cleavage of PARP, which is catalyzed by caspase-3 in apoptosis, was increased by JQ1 treatment in RBE cells only ( Figure 3C ). These data suggested that the induction of apoptosis contributed to the antigrowth effect of JQ1 in RBE cells. qRT-PCR showed upregulation of the proapoptotic genes BIM and BAX after JQ1 treatment in RBE cells only, but not in HuCCT1 cells ( Figure 3D ).
ChIP confirmed the increased level of the active transcription marker, histone H3 lysine 4 trimethylation (H3K4me3), at the promoter region of the two genes ( Figure 3E,F) .
| MYC gene is not a main target of JQ1 in RBE cells
The antiproliferative effects of JQ1 often depend on the suppression of MYC oncogene in various tumors. 26, 27 As the downregulation of MYC expression by JQ1 treatment was more evident in HuCCT1 To further investigate the possibility that the downregulation of MYC was involved in the mechanism of the antiproliferative effects of JQ1, MYC was stably knocked down in RBE cells ( Figure S1A ,B).
Suppression of MYC inhibited cell proliferation in RBE cells (Figure 4B) . MYC knockdown also activated caspase-3/7; however, the effect was not as great as that of JQ1 treatment and upregulation of BAX or BIM was not seen ( Figures 3B and 4C,D) . These findings indicated that the knockdown of MYC did not fully recapitulate the effects of JQ1 treatment, emphasizing the notion that MYC suppression was not a main mechanism of the antigrowth effect of JQ1 in RBE cells.
| IDH1 mutation enhances JQ1 sensitivity in ICC cells
As previously reported, 23 RBE cells, but not HuCCT1 cells, harbor an IDH1 mutation ( Figure S2 ). To examine the possibility that IDH1 mutation affects cellular sensitivity to JQ1, we first treated RBE cells with AGI-5198, a specific inhibitor of the IDH1 R132H mutant. 
| DISCUSSION
In the present study, we showed the possibility that JQ1 exerts a growth inhibitory effect on human ICC cells with an IDH1 mutation.
In BTC, standard chemotherapy using a combination of gemcitabine and cisplatin, has only limited therapeutic efficacy. 33 Recently, some specific therapies targeting newly identified molecular aberrations, such as fibroblast growth factor receptor 2 (FGFR2) gene fusion, have been proposed in ICC. [34] [35] [36] Based on preclinical studies showing that BTC harboring FGFR2 gene fusions are sensitive to FGFR inhibition, 37 several small molecule kinase inhibitors of FGFR have proceeded to clinical trials. 38, 39 Given that molecular targeting therapies rely on the targeted molecular status on which cancer cells depend, it is reasonable to stratify cancer cells based on their genomic profiles. In the present study, we propose that the IDH1 mutation is a factor for treatment stratification of ICC. There are other reports that mutant IDH increases the dependency of specific molecules, including BCL-2, NAMPT, and SRC. 23, 40, 41 Mutant IDH2 increased the susceptibility of leukemia cells to BET protein inhibition. 42 AGI-6780, a selective mutant IDH2 inhibitor, showed significant efficacy in IDH2-mutant leukemia cells through the induction of differentiation. 43 AGI-5198 inhibited the mutant IDH1-driven gliomagenesis from immortalized human astrocytes, but showed no effects on the growth of transformed cells. 44 Likewise, in this study, AGI-5198 itself did not affect the viability of IDH1-mutant ICC cells . Cells were treated with JQ1 at the indicated concentrations for 72 h, and viability was assessed by using CCK-8 assay. C, Caspase-3/7 activity of HuCCT1 cells stably transfected with wild-type IDH1 (Wild) or mutant IDH1 (R132S) were assessed after treatment with DMSO or JQ1 (1 μmol/ L) for 48 h. DMSO control = 1. Data are presented as mean ± SEM (n = 4, *P < 0.05, **P < 0.01, NS, not significant, Student's t test) ( Figure 5A ). AGI-5198 may be insufficient to inhibit the function of R132S mutant IDH1 whereas that was confirmed in R132H mutant IDH1. 32, 45 Thus, the development of more potent, and pan-IDH1 mutant inhibitors are expected.
In the present study, sensitivity to JQ1 was determined by apoptosis and occurred in a MYC-independent way. Recent studies have also shown that BET inhibitors induce apoptosis in cancer cells independently of MYC. [46] [47] [48] [49] BET inhibition upregulates gene expression of the pro-apoptotic protein BIM and activates the apoptotic pathway in several malignancies. 50, 51 These findings were consistent with our data that JQ1 upregulated the expression of BIM and BAX in RBE cells through enrichment of the transcriptionally active histone mark H3K4me3 at the promoter region of the genes ( Figure 3D-F) .
More than 40% of BTC, especially ICC, have genetic abnormalities of at least one chromatin remodeling gene. 
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